肺动脉高血压的个性化医学:利用人工智能预防死亡
Łukasz Ledziński1, Grzegorz Grześk1, Michał Ziołkowski1
1Department of Cardiology and Clinical Pharmacology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-168 Bydgoszcz, Poland.
Journal of clinical medicine
|December 11, 2025
概括
机器学习模型可以确定预测肺动脉高血压 (PAH) 存活率的关键因素. 本研究对个性化PAH患者管理和改善临床决策的临床参数进行了排名.
科学领域:
- 心脏病学 心脏病学
- 医疗信息学 医疗信息学
- 机器学习在医学中的应用
背景情况:
- 肺动脉高血压 (PAH) 具有显著的发病率和死亡率.
- 现有的PAH风险预测模型在澄清特定临床参数的预后重要性方面存在局限性.
- 这项研究侧重于机器学习来对PAH死亡率预测的临床特征进行排名,而不是验证现有的计算器.
研究的目的:
- 识别和排名临床参数对于预测肺动脉高血压 (PAH) 患者的死亡率至关重要.
- 开发和评估基于人工智能的PAH风险分层模型.
- 探索机器学习对于个性化PAH管理的实用性.
主要方法:
- 利用了波兰人口肺高血压数据库 (BNP-PL) 登记处的1755名成人肺高血压患者.
- 采用LASSO回归和顺序特征消除来减少特征.
- 构建并测试了一个XGBoost分类模型,其特征重要性通过Shapley添加式解释 (SHAP) 方法来解释.
主要成果:
- XGBoost模型实现了曲线下的面积为0.767,准确度为0.738,特异性为0.733,灵敏度为0.800.
- SHAP值成功对特征进行排名,证实了ESC风险分层表中发现的参数的重要性.
- 当地SHAP解释促进了个性化的特征重要性评估,提高了临床适用性.
结论:
- 一个基于人工智能的模型显示了对PAH死亡率的有希望的预测能力.
- 机器学习技术为个性化PAH患者管理提供了传统风险评估的宝贵补充.
- 这项研究为临床医生提供了一个新的工具,用于个性化的风险评估和决策在PAH.
相关概念视频
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
554
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
554
Pulmonary Hypertension: Classification and Pathogenesis
536
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
536
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
415
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
415
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
424
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
424
Peripheral Artery Disease III: Interprofessional Care
221
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
221
